A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

The purpose of this study is to measure how well LY3819253, alone or in combination with either LY3832479 (LY-CoV016) or VIR-7831, works against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.